CTSOCytosorbents Corp

Nasdaq cytosorbents.com


$ 0.80 $ -0.02 (-2.53 %)    

Thursday, 02-May-2024 15:56:45 EDT
QQQ $ 429.07 $ 5.38 (1.28 %)
DIA $ 382.31 $ 3.34 (0.88 %)
SPY $ 505.01 $ 4.68 (0.94 %)
TLT $ 88.87 $ 0.38 (0.43 %)
GLD $ 213.12 $ -0.66 (-0.31 %)
$ 0.8194
$ 0.84
$ 0.00 x 0
$ 0.00 x 0
$ 0.80 - $ 0.84
$ 0.78 - $ 4.29
157,191
na
36.59M
$ 1.11
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-14-2024 12-31-2023 10-K
2 11-09-2023 09-30-2023 10-Q
3 08-01-2023 06-30-2023 10-Q
4 05-02-2023 03-31-2023 10-Q
5 03-09-2023 12-31-2022 10-K
6 11-03-2022 09-30-2022 10-Q
7 08-02-2022 06-30-2022 10-Q
8 05-03-2022 03-31-2022 10-Q
9 03-10-2022 12-31-2021 10-K
10 11-04-2021 09-30-2021 10-Q
11 08-03-2021 06-30-2021 10-Q
12 05-04-2021 03-31-2021 10-Q
13 03-09-2021 12-31-2020 10-K
14 11-04-2020 09-30-2020 10-Q
15 08-04-2020 06-30-2020 10-Q
16 05-05-2020 03-31-2020 10-Q
17 03-05-2020 12-31-2019 10-K
18 11-05-2019 09-30-2019 10-Q
19 08-06-2019 06-30-2019 10-Q
20 05-07-2019 03-31-2019 10-Q
21 03-07-2019 12-31-2018 10-K
22 11-06-2018 09-30-2018 10-Q
23 08-02-2018 06-30-2018 10-Q
24 05-08-2018 03-31-2018 10-Q
25 03-08-2018 12-31-2017 10-K
26 11-09-2017 09-30-2017 10-Q
27 08-07-2017 06-30-2017 10-Q
28 05-08-2017 03-31-2017 10-Q
29 03-03-2017 12-31-2016 10-K
30 11-07-2016 09-30-2016 10-Q
31 08-09-2016 06-30-2016 10-Q
32 05-09-2016 03-31-2016 10-Q
33 03-09-2016 12-31-2015 10-K
34 11-13-2015 09-30-2015 10-Q
35 08-13-2015 06-30-2015 10-Q
36 05-11-2015 03-31-2015 10-Q
37 03-31-2015 12-31-2014 10-K
38 11-12-2014 09-30-2014 10-Q
39 08-12-2014 06-30-2014 10-Q
40 05-14-2014 03-31-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-neutral-on-cytosorbents-maintains-1-price-target

HC Wainwright & Co. analyst Sean Lee reiterates CytoSorbents (NASDAQ:CTSO) with a Neutral and maintains $1 price target.

 recap-cytosorbents-q4-earnings
Recap: CytoSorbents Q4 Earnings
03/14/2024 21:05:07

 cytosorbents-q4-2023-gaap-eps-012-beats-014-estimate-sales-8700m-miss-9285m-estimate

CytoSorbents (NASDAQ:CTSO) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.14) ...

 earnings-scheduled-for-march-14-2024

Companies Reporting Before The Bell • Pharming (NASDAQ:PHAR) is projected to report earnings for its fourth quarter.

 cytosorbents-reports-outcomes-from-a-randomized-controlled-trial-using-cytosorb-blood-purification-during-heart-transplant-recently-published-in-the-european-society-of-cardiology-journal-esc-heart-failure

Better hemodynamic stability and lower rates of post-operative shock Patients in the CytoSorb group had lower median Vaso...

 hc-wainwright--co-downgrades-cytosorbents-to-neutral-lowers-price-target-to-1

HC Wainwright & Co. analyst Sean Lee downgrades CytoSorbents (NASDAQ:CTSO) from Buy to Neutral and lowers the price targ...

 gold-moves-lower-us-crude-stocks-decline-last-week

U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 100 points on Thursday. The Do...

 why-douyu-international-shares-are-trading-higher-by-14-here-are-other-stocks-moving-in-thursdays-mid-day-session

Shares of DouYu International Holdings Limited (NASDAQ: DOYU) rose sharply during Thursday’s session after announcing a share ...

 crude-oil-down-1-us-wholesale-inventories-fall-in-november

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 50 points on Thursday. The Dow tr...

 dow-gains-50-points-us-jobless-claims-rise-to-218000

U.S. stocks traded higher this morning, with the Dow Jones index gaining over 50 points on Thursday. Following the market open...

 why-is-blood-purification-focused-cytosorbents-trading-lower-today

CytoSorbents Corporation (NASDAQ: CTSO) released an update on the initial data analysis of primary safety and effectiveness end...

 cytosorbents-provides-update-on-star-t-trial-says-independent-dsmb-concluded-there-were-no-issues-with-device-safety

The Company has also performed the initial data analysis on the primary effectiveness endpoint of STAR-T. Based on this analysi...

 recap-cytosorbents-q3-earnings
Recap: CytoSorbents Q3 Earnings
11/09/2023 21:50:20

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION